Skip to main content
Clinical Trials/NCT05376046
NCT05376046
Recruiting
Not Applicable

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease

BILLOIR1 site in 1 country200 target enrollmentSeptember 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sickle Cell Disease
Sponsor
BILLOIR
Enrollment
200
Locations
1
Primary Endpoint
Hospitalisation for Vaso-occlusive crisis within one years
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation.

The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.

Registry
clinicaltrials.gov
Start Date
September 1, 2018
End Date
September 1, 2026
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
BILLOIR
Responsible Party
Sponsor Investigator
Principal Investigator

BILLOIR

Associate Professor

University Hospital, Rouen

Eligibility Criteria

Inclusion Criteria

  • Sickle cell disease

Exclusion Criteria

  • \<18 years
  • pregnancy
  • Patient under protective guardianship or curatorship

Outcomes

Primary Outcomes

Hospitalisation for Vaso-occlusive crisis within one years

Time Frame: 1 year

Following injury consultation, evaluation of biological markers predicting vaso-occlusive crisis requiring hospitalisation in the year

Study Sites (1)

Loading locations...

Similar Trials